Drug Profile
Research programme: L-nucleoside conjugates - OncoVista
Alternative Names: b-L-dU/b-D-5FUdRLatest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Genencor International; Lipitek International
- Developer OncoVista
- Class Drug conjugates; Nucleosides
- Mechanism of Action Thymidylate synthase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Cancer in USA (IV)
- 14 Jul 2011 Preclinical trials in Cancer in USA (IV)
- 17 Jan 2008 OVI 117 is undergoing GLP animal drug safety studies